Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 5
Submit an article Journal homepage
223
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Does outcome of second salvage therapy in relapsed or refractory acute myeloid leukemia depend on intensity of either first or second salvage therapy?

Daisuke ArakiDepartment of Medicine, University of Washington, Seattle, WA, USA;
,
Megan OthusPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA;
,
Roland B. WalterDepartment of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA; ;Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
,
Pamela S. BeckerDepartment of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA; ;Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
,
Vicky SandhuClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
&
Elihu H. EsteyDepartment of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA; ;Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USACorrespondence[email protected]
Pages 1205-1207 | Received 11 May 2015, Accepted 26 Jul 2015, Published online: 23 Dec 2015

References

  • Estey E, Kornblau S, Pierce S, et al. A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia. Blood. 1996;88:756.
  • Estey EH. Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia. 2000;14:476–479.
  • Othus M, Appelbaum FR, Petersdorf SH, et al. Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant. 2015;21:559–564.
  • Giles F, O’Brien S, Cortes J, et al. Outcome of patients with acute myelogenous leukemia after second salvage therapy. Cancer. 2005;104:547–554.
  • Quintás-Cardama A, Ravandi F, Liu-Dumlao T, et al. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood. 2012;120:4840–4845.
  • Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30:2670–2677.
  • Burnett AK, Russell NH, Hunter AE, et al. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood. 2013;122:1384–1394.
  • Estey E, Levine RL, Löwenberg B. Current challenges in clinical development of “targeted therapies”: the case of acute myeloid leukemia. Blood. 2015;125:2461–2466.
  • Nazha A, Ravandi F. Acute myeloid leukemia in the elderly: do we know who should be treated and how? Leuk Lymphoma. 2014;55:979–987.
  • Laszlo GS, Estey EH, Walter RB. The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood. 2014;28:143–153.
  • Estey EH. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia. Leukemia. 2013;27:1803–1812.
  • Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453–474.
  • Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21:4642–4649.
  • Araki D, Othus M, Walter RB, et al. Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia. Haematologica. 2015;100:e254–e256.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.